Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 9/2011

01-09-2011 | Research Articles

Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients

Authors: Carmen Balañá, Cristina Carrato, José Luis Ramírez, Andrés Felipe Cardona, Mireia Berdiel, José Javier Sánchez, Miquel Tarón, Cristina Hostalot, Eva Musulen, Aurelio Ariza, Rafael Rosell

Published in: Clinical and Translational Oncology | Issue 9/2011

Login to get access
Metadata
Title
Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients
Authors
Carmen Balañá
Cristina Carrato
José Luis Ramírez
Andrés Felipe Cardona
Mireia Berdiel
José Javier Sánchez
Miquel Tarón
Cristina Hostalot
Eva Musulen
Aurelio Ariza
Rafael Rosell
Publication date
01-09-2011
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 9/2011
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-011-0714-x

Other articles of this Issue 9/2011

Clinical and Translational Oncology 9/2011 Go to the issue

Educational Series/Blue Sries

Gastric tumours in hereditary cancer syndromes: clinical features, molecular biology and strategies for prevention

Research Articles

Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health

Educational Series/Yellow Series

Multidisciplinary approach in stage III non-small-cell lung cancer: standard of care and open questions

Research Articles

A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study

Correspondence

The present and future of radiation oncology in Spain

Research Articles

Prognosis of patients with thyroid cancer who do not undergo surgical treatment: a SEER database analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits